.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Novartis
Citi
Deloitte
Federal Trade Commission
Medtronic
Cipla
Healthtrust
Baxter
Express Scripts

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Inventor(s): Lee; Francis Y. F. (Yardley, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:May 20, 2004
Application Number:10/850,072
Claims:1. A method for treating lung cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula, ##STR00020## or a pharmaceutically-acceptable hydrate, solvate, or geometric, optical or stereoisomer of Compound (1), and a dosage unit of at least a second chemotherapeutic agent comprising antibody C225, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the antibody C225 alone.

2. The method of claim 1 wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.

3. The method of claim 1 wherein the antibody C225 is administered following the administration of Compound (1).

4. The method according to claim 1, wherein the antibody C225 is administered before the administration of Compound (1).

5. The method according to claim 1, wherein the antibody C225 is administered substantially simultaneously with the administration of Compound (1).

6. The method according to claim 1, wherein the antibody C225 and the Compound (1) are both administered parenterally.

7. The method according to claim 1, wherein the cancer is non-small cell lung cancer.

8. A method for treating pancreatic cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula, ##STR00021## and/or a pharmaceutically-acceptable hydrate, solvate, and/or geometric, optical or stereoisomer of Compound (1), and a dosage unit of at least a second chemotherapeutic agent comprising antibody C225, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the antibody C225 alone.

9. The method of claim 8, wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.

10. The method of claim 7, wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Medtronic
Cantor Fitzgerald
Citi
Chubb
Teva
Farmers Insurance
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot